Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 142Myelodysplastic Syndromes 66Leukemia, Myelomonocytic, Chronic 33Neoplasms 17Leukemia 16Recurrence 14Hematologic Neoplasms 14Multiple Myeloma 11Lymphoma, Non-Hodgkin 9Lymphoma 7Carcinoma, Non-Small-Cell Lung 6Primary Myelofibrosis 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myeloproliferative Disorders 5Lymphoma, Large B-Cell, Diffuse 5Leukemia, Lymphocytic, Chronic, B-Cell 5Neoplasm Metastasis 4Leukemia, Myeloid 4Hodgkin Disease 4Hematologic Diseases 4Prostatic Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Glioblastoma 3Breast Neoplasms 3Anemia, Refractory, with Excess of Blasts 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Renal Insufficiency 2

Interventions

venetoclax 1quizartinib 1Daunorubicin 1Cytarabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Sarcoma, Myeloid × Azacitidine × Clear all
NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡